There is now good evidence suggesting that MCL-1 mediates basal breast cancer cell survival and therapeutic resistance, with several studies showing the importance of this protein in therapeutic resistance where its suppression or antagonism is important for re-sensitization to cytotoxic therapies [146,161,162,163]. This evidence concerns the gene MCL1 and breast carcinoma.